7/1/2013

Raptor Pharmaceutical's Procysbi, or cysteamine bitartrate, was recommended for approval by the European Committee for Medicinal Products for Human Use as a treatment for nephropathic cystinosis. The drug was approved in the U.S. earlier this year.

Related Summaries